Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-four patients with severe steroid-dependent asthma participated in a double-blind cross-over study performed in two centers. After a run-in period of 2 weeks when beclomethasone dipropionate (BDP) (400 micrograms/day) was used, the patients were treated for 4 weeks with either a high-dose (1600 micrograms/day) or a low-dose (400 micrograms/day) of budesonide (Pulmicort). Thereafter the doses of budesonide were switched and the treatment continued for a further 4-week period. Patients treated with high-dose budesonide displayed significant improvements in airway functions. In addition, subjective scores for cough, sputum production and dyspnoea were more improved in the high-dose group than in the low-dose group. The need for concomitant beta 2-agonist therapy was also significantly reduced during the high-dose treatment. No significant changes in plasma cortisol levels were detected and no adverse effects of importance were registered. The results indicate that high-dose budesonide treatment improves the clinical status of patients with severe steroid-dependent asthma more than a low-dose therapy but without causing systemic side-effects.
 ...
PMID:Effect of inhaled budesonide on severe steroid-dependent asthma. 355 2

Budesonid is a topical corticosteroid for application by inhalation with a high anti-inflammatory effect. 25 patients (15 women, 10 men, average age 45.3 years) with intrinsic asthma requiring corticosteroids were treated for an average of 36 days with budesonid (Pulmicort dosage aerosol, Astra Sweden) in a dose of 3 X 400 micrograms per day. The basic therapy with beta sympathicomimetics, theophylline preparations and systemic corticosteroids was continued. Changes in the plasmacortisol level (PCS) and the course of the asthma were studied under reduction of the systemic corticosteroid dosage. The mean reduction in dosage of the systemic corticosteroid achieved was almost 2/3 of the initial dosage (p 0.001). The pathologically reduced PCS at the start of the study normalized in 13 patients (52%) to values within the standard range. A significant (p 0.001) mean increase in PCS of 43% was achieved. The eosinophils in the blood underwent no significant change. The peak flow improved by a mean 26% (p 0.001) with respect to the initial values. Despite a reduction in systemic corticosteroids, the symptoms of breathlessness, coughing and expectoration improved or declined practically without exception. Apart from some temporary hoarseness and throat irritation in 5 patients, there were no undesired side effects or incompatibility.
 ...
PMID:[Results of treatment with budesonide (Pulmicort) in corticosteroid-dependent intrinsic asthma]. 408 78

The effect of intranasally administered corticosteroid (budesonide) on nasal symptoms, mode of respiration (nasal versus mouth breathing), and asthma was investigated in 37 asthmatic children who were mouth breathers because of chronic nasal obstruction. After a 2-wk run-in period, the children were allocated randomly to 4 wk of intranasal therapy with either budesonide (400 micrograms/day) or placebo spray. A double-blind, parallel design was used. Diaries for peak expiratory flow, asthma, and rhinitis symptom scores and degree of mouth breathing were recorded at home. Nasal eosinophilia, nasal airway resistance at a flow of 0.2 L/s (NAR0.2), and lung function at rest and after exercise challenge were assessed at the clinic immediately before and at end of the 4-wk treatment. Budesonide, when compared with placebo, significantly decreased nasal obstruction (p less than 0.05), secretion (p less than 0.01), and eosinophilia (p less than 0.02), as well as NAR0.2 (p less than 0.05) and mouth breathing (p less than 0.01). The improvement in nasal obstruction correlated closely to the changes in mouth breathing (r = 0.80, n = 17, p less than 0.001). Furthermore, intranasally administered budesonide resulted in less exercise-induced asthma (EIA) (p less than 0.02) and decreased cough and asthma severity significantly. Pulmonary mechanics were only marginally improved. The present study showed that intranasally administered budesonide is effective in the treatment of perennial allergic rhinitis. An attenuation of EIA and a tendency to less asthma after budesonide therapy suggest a decrease in bronchial reactivity, but the results gave no clear evidence of an association between nasal airway function and asthma.
 ...
PMID:Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. 650 97

The efficacy of beclomethasone dipropionate aerosol (BDA) 100 micrograms q.i.d. was compared with that of budesonide aerosol 10 micrograms q.i.d. in 17 patients. The efficacy of inhaled BDA 100 micrograms q.i.d. was also compared with that of budesonide 50 micrograms q.i.d. with and without an extension tube (Inhalet) attached to the actuator in 23 patients. Both studies included placebo periods. The trials were performed with the cross-over technique in patients with stable asthma. Each treatment was randomized and given in periods of two weeks starting with a run-in period. The patients recorded peak expiratory flow rates (PEF) twice daily and filled in diary cards for cough, wheeze, breathing difficulties and use of beta 2-receptor stimulant aerosol. In the first study the patients came to the hospital twice weekly throughout the trial for spirometry and interview. In the second study they came every second week. Budesonide and BDA were superior to placebo. Budesonide in doses of 100 micrograms and 50 micrograms were as efficacious as BDA 100 micrograms q.i.d., while budesonide 50 micrograms q.i.d. with Inhalet was slightly more effective. Treatment for two weeks was found to be sufficient. For each parameter the average of the last four days of each period was found to be relevant in the comparison. The placebo period should preferably not be placed at random in the trial, but as the last treatment period.
 ...
PMID:Methodological aspects on clinical trials with inhaled corticosteroids: results of two comparisons between two steroid aerosols in patients with asthma. 695 74

The authors examined 85 children who had serious recurrent pseudogroup syndrome, and re-examined them 1-3 years later. 1/3 of the patients was also allergic, mostly to mites and grasspollens. The patients got either regular, daily two inhalation, or their parents were taught to inspire the drug in the case of stenotic cough of hoarseness. Half of the patients did not answer to our letter. The parents of 43 patients answered and described their observations according to the inquiry letter. 2/3 of treated children either amolioreted definitely of became symptom free. 12 patients had 30 laryngeal attacks before the budesonide treatment whereas only 3 attacks, needing hospitalisation, occurred after the budesonide treatment. 6 patients experienced definite amelioration and two children's state worsened. Budesonide therapy seemed to be useful in the prevention and therapy of recurrent laryngitic children. Further experiences using turbo-inhaler and placebo would be important for more definite statement. Nevertheless inhalative budesonide is the first drug promising fast remission of laryngeal edema.
 ...
PMID:[Management of childhood pseudocroup with budesonide inhalation]. 780 Mar 89

Forty-seven patients with pulmonary sarcoidosis stage II-III, fulfilling clinical indications for starting treatment with corticosteroids, received oral methylprednisolone for 8 weeks in gradually decreasing doses (starting dose 48 mg per day). From week 5 onwards, they also received inhaled budesonide, 1.6 mg daily. Treatment was continued for 18 months and all patients have been followed for at least 3 years. At 18 months treatment could be discontinued in 38 patients, who had used individually adjusted doses of budesonide depending on the clinical response (reduced doses in 14, initial dose in 16, and increased doses in 8 patients). Budesonide treatment alone was satisfactory in 31 of these 38 cases. An additional seven patients could stop treatment after receiving supplementary courses of oral steroids for 3-12 months. Treatment is ongoing in 9 patients in which 6 have extrapulmonary manifestations requiring oral steroids. The chest radiograph became normal in 22 patients and improved in 14. Significant improvements were noted in FVC and DLco in relation to predicted normal values. Serum ACE, lysozyme and beta 2-microglobulin values decreased significantly. Transient cough was seen in 5 and hoarseness in 3 patients. No systemic side-effects were noted; one patient taking 2.4 mg budesonide daily had a plasma cortisol value below the normal range. Inhaled budesonide seems to offer an effective and safe alternative to oral steroids for long-term maintenance treatment of patients with pulmonary sarcoidosis.
 ...
PMID:Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. 780 97

An effect of a 6-week therapy with Budesonide forte aerosol Polfa on the course of bronchial asthma has been investigated in 30 atopic asthmatics with double-blind trial. The drug has been administrated in the dose of 200 micrograms four times daily and the results have been compared with placebo and foreign made analogue. Twelve patients required chronic administration of oral glucocorticosteroids in the daily dose of 9.2 mg of prednisone. Dyspnoea, cough, doses of bronchodilators and oral corticosteroids, pulmonary function and bronchial reactivity to histamine have been considered in the clinical analysis. A decrease in the severity of dyspnoea and in the doses of used bronchodilators as well as intensity of cough have been observed during the treatment with inhaled steroids. The mean daily dose of prednisone has decreased to 5.8 mg and oral corticosteroids could be withdrawn in 4 of the patients treated chronically with these drugs. Budesonide forte significantly reduced bronchoconstriction and bronchial reactivity to histamine, compared with baseline values.
 ...
PMID:[Clinical evaluation of budesonide forte action in patients with atopic bronchial asthma]. 841 65

The aim of this study was to investigate whether budesonide, for 10 d, administered at the first sign of an upper respiratory tract infection, could reduce asthma symptoms in 1-3-y-old children with asthma during infections. The primary efficacy variable was symptom scores. The study had a multicentre, randomized, double-blind, placebo-controlled design with parallel groups. Fifty-five children with a mean age of 26 months received either budesonide or placebo via a spacer with a facemask. Each child was monitored for 1 y. Budesonide was given 400 microg q.i.d. for the first 3 d and b.i.d. for 7 d. Symptoms (cough, wheeze, noisy breathing and breathlessness) were scored (0-3) daily by the parents. Asthma symptom scores were lower in children treated with budesonide than in those given placebo. The effect was most pronounced for cough and noisy breathing, but it did not affect the need for hospital care. In conclusion, treatment with budesonide, started at the first sign of a respiratory infection, reduced asthma symptoms in toddlers with episodic asthma.
 ...
PMID:Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. 1009 May 46

In two studies comparing budesonide delivered by Turbuhaler with budesonide delivered by pressurized metered dose inhaler (pMDI), a significantly higher morning peak expiratory flow (PEF), and a patient preference in favor of budesonide by Turbuhaler was found. Less cough was also noted. In a third study no difference was found between the two formulations. However, a meta-analysis of the three studies demonstrated a significant difference in favor of budesonide by Turbuhaler for forced expiratory volume in one second (FEV1) and morning PEF. These findings are supported by data on lung deposition showing the Turbuhaler to be twice as efficient as a pMDI. At the same time, the availability of budesonide from the gastrointestinal tract is reduced. Thus, a more beneficial ratio arises between local lung delivery and systemic availability. Inhaled glucocorticosteroids are now recommended for mild asthma. Thus once daily treatment with 400mug budesonide by Turbuhaler has been studied in two trials; a comparison with 200mug twice daily was also made. In both studies morning/evening PEF increased significantly over placebo and no difference was demonstrated between once- and twice-daily treatments. A study to determine the effect of placebo and 200mug twice daily and 400mug once daily of budesonide by Turbuhaler on 24-h plasma and urinary cortisol demonstrated no difference between the treatment regimens. Budesonide by Turbuhaler is at least as effective as budesonide by pMDI. When patients are switched to budesonide by Turbuhaler an attempt should be made to reduce the dose.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Clinical efficacy and safety of budesonide Turbuhaler in adults. 1014 82

We report two cases in whom inhaled corticosteroid rapidly improved pulmonary sarcoidosis. In the first case, fluticasone at 400 microg/day was initiated, because dry cough and small nodular shadows on chest X-ray persisted for six months. But her cough and the nodular shadows were persisted, therefore the treatment was replaced with budesonide at 800 microg/day. Two months later, her dry cough subsided and pulmonary shadows improved. Serum angiotensin-converting enzyme (ACE) level was decreased and pulmonary function improved. In the second case, bumethasone was already administered at a local clinic. Budesonide at 400 microg/day was combined with oral steroid, because pulmonary shadows continued for eight years. Also two months later, the serum ACE level was decreased and the pulmonary shadows slightly improved. Inhaled corticosteroid therapy for two to three months is tolerable, and may be a useful treatment option in some patients with sarcoidosis.
 ...
PMID:Inhaled corticosteroid rapidly improved pulmonary sarcoidosis. 1641 49


1 2 Next >>